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transcriptional enhancers are a primary mechanism by which tissue-specific gene expression is achieved. despite the importance of these regulatory elements in development, responses to environmental stresses and disease, testing enhancer activity in animals remains tedious, with a minority of enhancers having been characterized. here we describe 'enhancer-FAcs-seq' (eFs) for highly parallel identification of active, tissue-specific enhancers in Drosophila melanogaster embryos. Analysis of enhancers identified by eFs as being active in mesodermal tissues revealed enriched dnA binding site motifs of known and putative, previously uncharacterized mesodermal transcription factors. naive Bayes classifiers using transcription factor binding site motifs accurately predicted mesodermal enhancer activity. Application of eFs to other cell types and organisms should accelerate the cataloging of enhancers and understanding how transcriptional regulation is encoded in them.
In metazoans, gene expression is regulated in a tissue-specific manner predominantly via noncoding genomic regions referred to as cis-regulatory modules (CRMs) that regulate the expression of typically the nearby gene(s) 1 . CRMs contain one or more DNA binding sites for one or more sequence-specific transcription factors that activate or repress gene expression. CRMs that activate gene expression are frequently referred to as transcriptional enhancers 2 .
The fruit fly D. melanogaster has served as a powerful model organism for studies of transcriptional enhancers 2 . It has been estimated that there are ~50,000 enhancers in the D. melanogaster genome 3 , yet to date the tissue-specific activities of only ~1,800 are known 4 . Technology for identifying enhancers active in particular cell types would aid in defining functional cis-regulatory elements and would facilitate computational identification of sequence highly parallel assays of tissue-specific enhancers in whole Drosophila embryos features important for cell type-specific enhancer activity. Currently, regions identified by chromatin immunoprecipitation (ChIP) to be occupied by transcription factors are tested by lowthroughput, traditional reporter assays 5, 6 . Automated image analysis of reporter assays in embryos 3, 7 requires vast infrastructure and resources. Although highly parallel reporter assays have been developed recently [8] [9] [10] [11] [12] [13] , none directly identify enhancer activity in a genomic context (integrated into the genome) in particular cell types of interest in a whole animal.
Our technology, termed 'enhancer-FACS-seq' (eFS), achieves highly parallel identification of active, tissue-specific transcriptional enhancers in whole Drosophila embryos ( Fig. 1a and Supplementary Fig. 1 ). As with traditional enhancer assays, each candidate CRM (cCRM) is cloned upstream of a reporter gene.
Our key innovation is the replacement of microscopy to screen for tissue-specific enhancers with FACS of dissociated cells. In each fly, one marker (here, rat CD2 cell-surface protein 14 ) is used to label cells of a specific tissue for FACS, and the other marker (here, GFP) is used as a reporter of cCRM activity. Cells are sorted by tissue type and then by GFP fluorescence, allowing screening of hundreds of cCRMs in a time-efficient and costefficient manner.
results library of candidate cis-regulatory modules
We focused on embryonic mesoderm as our model system because it comprises a variety of cell types, the major regulatory factors governing mesoderm development are conserved between vertebrates and Drosophila 15 , and many data sets are available for genomic features associated with active enhancers. We created a plasmid library of hundreds of reporter constructs for ~1-kb cCRMs (Supplementary Note 1 and Supplementary Table 1 ) composed of sequences located next to mesodermally expressed genes and in addition having one of the following features: regions identified by ChIP 6 as bound by at least one of the somatic mesoderm transcription factors Twist (Twi), Tinman (Tin) or Myocyte enhancing factor 2 (Mef2); regions identified as bound by the transcriptional coactivator CREB binding protein (CBP) 16, 17 ; regions containing DNase I-hypersensitive sites (DHS) 18 ; dense clusters of evolutionarily conserved motif occurrences for mesodermal transcription factors 19 ; and additional regions surrounding mesodermal genes not covered by the aforementioned features (Supplementary Note 2).
eFs experiments
In our cCRM plasmid library, each cCRM flanked by attL sites was cloned into a vector that contains attR sites for Gateway cloning, the phiC31 attB site, the mini-white (mini-w) gene and a reporter cassette comprising the Hsp70 minimal promoter driving expression of a nuclear localization signal-tagged EGFP gene with an SV40 polyadenylation sequence. We injected the library into two batches of Drosophila embryos carrying a single phiC31 attP site on the second chromosome. This strain of flies expresses a nuclearlocalized phiC31 integrase under the control of the nanos (nos) promoter, which causes mRNA to be produced during oogenesis and deposited in the egg before fertilization. The recombination of an attP and an attB site, mediated by the phiC31 integrase, produces an attL and an attR site (distinct from and not cross-reacting with those used in the Gateway system), which are not themselves substrates for the integrase; thus, integration is nonreversible and one integration event destroys the attP site used, preventing any further events at that genomic locus. Each resulting embryo has one GFP reporter under the control of one cCRM integrated at the same genomic site by the phiC31 integrase 20 . Use of a sitespecific integrase avoids artifacts that would result if more than one cCRM were present in a cell and also avoids potential position effects on enhancer activity. In the first batch, we injected ~3,500 embryos and crossed transformant males (selected by eye color) to females from two different CD2 lines to identify enhancers active in distinct tissues: twi:CD2 for whole mesoderm, and I-E D5 : CD2 (Mef2-I-E D5 :CD2) for a subset 21 of largely fusion-competent myoblasts (FCMs). In the second batch, we injected ~4,500 embryos and crossed transformant males to duf:CD2 females to identify activity in somatic mesoderm founder cells 22 .
At developmental stages 11-12, we dissociated embryos and purified them by FACS. From the twi:CD2 embryos, we collected ~315,000 GFP + CD2 + cells and ~198,000 GFP + CD2 − cells as well as 1 × 10 6 'input' cells regardless of GFP status (Online Methods, Fig. 1b, Supplementary Fig. 2 and Supplementary Table 2 ). We collected fewer GFP + CD2 + cells from the Mef2-I-E D5 :CD2 and duf:CD2 embryos ( Supplementary Table 2 ) because the Mef2-I-E D5 enhancer is active in ~50-fold fewer cells than the twi enhancer, which is active in roughly 50,000 cells at this stage, whereas the duf enhancer is active only in most of the 660 founder cells per embryo, nearly an order of magnitude fewer cells than for the Mef2-I-E D5 enhancer.
We extracted genomic DNA from the collected cells, amplified the cCRMs by PCR and sequenced the resulting amplicons on the Illumina platform. We mapped the sequencing reads ( Fig. 1c and Supplementary Table 3 ) to the D. melanogaster genome using segemehl software 23 (Supplementary Fig. 3 ). We detected 213 and 400 cCRMs (false discovery rate (FDR) < 5 × 10 −5 ; Online Methods) as having integrated into the fly genome from the first and second batches of injections, respectively. The greater number of cCRMs detected from the second batch was likely due to the fact that we collected transformant progeny from more injected embryos.
To evaluate the enhancer activity of the detected cCRMs, we calculated each cCRM's enrichment in a particular cell population as compared to the corresponding 'input' sample ( Fig. 1a) using DESeq software 24 . The input sample provides information on the baseline read counts resulting from cCRM representation in the embryo populations. In control experiments CD2 + and CD2 − npg cells exhibited no major differences in their cCRM content ( Fig. 1d) . Therefore, we used CD2 + cells as input sample for so-called 'twi:CD2 + GFP + ' cells, whereas for the rarer FCM and founder cell types, we used CD2 − cells as input ( Supplementary Fig. 2 ). In total, by eFS we identified 150 of the detected cCRMs as being active enhancers (adjusted P value (P adj ) < 0.1) in at least one cell population. Of these, 57 were active mesodermal enhancers: 34 in whole mesoderm ( Fig. 2a) , 18 in FCMs and 20 in founder cells ( Supplementary Fig. 4 ). Of these 57 active mesodermal cCRMs, 12 overlapped by at least 100 base pairs (bp) with a known mesodermal enhancer at an overlapping developmental time point in the REDfly database 25 ( Supplementary  Table 4 ), and the remaining 45 were putative new mesodermal enhancers, including 16 in FCMs and 14 in founder cells. Analysis of GFP + CD2 − cells collected from twi:CD2, Mef2-I-E D5 :CD2 and duf:CD2 embryos revealed 93 putative nonmesodermal enhancers ( Fig. 2b and Supplementary Table 4 ). Comparing to enhancers identified from a recent screen of a genomic DNA library for enhancer activity in the S2 cell line and in cultured ovarian somatic cells 13 , only 13 of the 57 mesodermal enhancers and 11 of the 93 nonmesodermal enhancers identified by eFS overlap by at least 100 bp with enhancers found in that study. This comparison highlights the value of eFS for identifying enhancers active in particular cell types of interest in whole embryos.
Validation of eFs results
To validate our eFS results, we performed traditional reporter assays in whole Drosophila embryos (Online Methods). For the twi:CD2 + eFS data, we tested 69 of the cCRMs, including: 21 putative active mesodermal enhancers (P adj < 0.1) and 48 putative inactive cCRMs (P adj > 0.1). The specificity of eFS was excellent among significantly enriched cCRMs: 18 of the 21 tested putative mesodermal enhancers drove expression in mesoderm at stages 11-12 ( Fig. 3 and Supplementary Fig. 5 ). eFS exhibited moderate sensitivity for significantly enriched enhancers that were active in relatively few mesodermal cells: nine enhancers had expression patterns that were manually assessed as 'widespread coexpression' (expression in a majority of strongly twi:CD2 + cells) (for example, cCRMs named CBP2862 and ChIPCRM3152; Fig. 3 ), and the other nine drove 'limited coexpression' in smaller subsets of twi: CD2 + cells (for example, ChIPCRM3429 and CBP5467; Fig. 3 ). Fig. 5 and Supplementary Table 4 ). Some of these eFS false negatives drove expression in cells that expressed low levels of CD2 and might have been missed by our relatively stringent FACS gate for collecting twi:CD2 + cells. In most cases, the observed expression domain was linked to an adjacent gene's expression ( Supplementary Table 5 ). Although the data are slightly noisier for FCM and founder cell enhancers (6 of 9 tested putative FCM enhancers and 9 of 11 tested putative founder cell enhancers drove mesodermal expression; Supplementary Fig. 5 ), likely because we collected roughly 20-fold fewer CD2 + GFP + cells from the more specific Mef2-I-E D5 :CD2 and duf:CD2 lines, the results nevertheless demonstrate that eFS can identify enhancers active in rarer cell types. In addition, the majority of cCRMs identified by eFS as active in any of the three CD2 − GFP + cell collections (35 of 47 cCRMs tested) were indeed active at this developmental stage (Supplementary Table 6 ).
Twelve of the 48 putative inactive cCRMs drove 'limited coexpression' (Supplementary

comparisons of eFs data to other genomic data types
We examined the eFS-identified enhancers for enrichment of known enhancer-associated chromatin marks. Comparison to data from batch isolation of tissue-specific chromatin for immunoprecipitation (BiTS-ChIP) for mesodermal cells from stage 10-11 embryos 26 showed that acetylation of histone H3 on npg (H3K4me1), H3K4 trimethylation (H3K4me3), H3K79me3 and occupancy by RNA polymerase II [26] [27] [28] [29] were enriched (area under receiver operating characteristic curve (AUC) ≥ 0.6, P < 0.05 by Wilcoxon-Mann-Whitney U test) among enhancers found to be active in mesoderm by eFS ( Fig. 4a) . However, in contrast to a prior report that H3K27me3 was depleted among active mesodermal enhancers 26 , we found H3K27me3 to be enriched among mesodermal enhancers. We also observed enrichment of H3K27ac, H3K4me1 and H3K9ac when comparing modENCODE data for 4-8-h whole embryos 17 to active enhancers identified by eFS in duf:CD2 − cells, which approximate whole embryo samples ( Fig. 4b and Supplementary Note 3) . Although H3K9ac is known as a mark of active transcription start sites 30 , our observed enrichment of H3K9ac among active enhancers supports the observation of H3K9ac in the 'strong enhancer' chromatin state in human cells 31 .
Our enhancer data allowed us to investigate which genomic data types 6, [16] [17] [18] provide the greatest utility in identifying enhancers. Occupancy by sequence-specific transcription factors (Twi, Tin, Mef2, Bagpipe (Bap) and Biniou (Bin)) expressed specifically in the mesoderm was most enriched among active mesodermal enhancers ( Fig. 4c and Supplementary Fig. 6 ). DHSs 18 were nearly as enriched as enhancer-associated histone modifications ( Fig. 4b, Supplementary Fig. 6 ). Among enhancers found in whole mesoderm, we observed the greatest enrichment for regions bound by Tin at 2-4 h (stages 5-7), suggesting that Tin might be a pioneer factor 32 that premarks mesodermal enhancers that are active later in development. These same Tin-bound enhancers exhibited enhanced Tin binding at 4-6 h (stages 8-9; data not shown) and were consistent with tin being essential for specification of ventral founder cells 33 and also with tin activity and putative Tin binding sites being required for the activity in ventral muscle progenitors of an enhancer that does not become expressed until after Tin protein expression has become restricted to the dorsal mesoderm 34 . Our observed enrichment of Mef2, Twi and Tin occupancy at 4-6 h or 6-8 h (stages 10-11) among enhancers identified from Mef2-I-E D5 :CD2 + cells supports the role of Mef2, Twi and Tin in regulating FCM genes coordinately with Lameduck (Lmd) 35 .
enrichment of transcription factor binding site motifs
We separately analyzed each of the three sets of eFS-identified mesodermal enhancers (whole mesoderm, FCMs or founder cells) for over-represented motifs and pairwise motif combinations that might be required for enhancer activity. We used the PhylCRM and Lever algorithms 19 to determine enrichment of matches, scored according to their evolutionary conservation, to 567 publicly available Drosophila transcription factor binding site motifs 6, [35] [36] [37] [38] (Online Methods). Many motifs were significantly enriched (AUC ≥ 0.65, FDR ≤ 0.1) either individually or in pairwise combination ( Fig. 5a, Supplementary Figs. 7  and 8, and Supplementary Table 7) for the whole-mesoderm and FCM enhancers.
For each of these two sets of enhancers, we observed strong enrichment of the primary, known master regulator of that cell population: Twi for whole mesoderm 39 and Lmd for FCMs 21, 40 . We found motifs for other known mesodermal regulators in enriched combinations, including Bap, Lola-PC and Mef2 in whole mesoderm, and Twi and Mef2 in FCMs. We also saw strong enrichment of motifs for sequence-specific DNA-binding proteins z, grh and Trl (also known as GAGA factor (GAF)) that participate in recruitment of chromatin-modifying PcG and trxG proteins 41 , supporting prior findings of the enrichment of the z and/or Trl motifs among regions bound by Mef2, Twi or Tin in ChIPmicroarray studies 42 . For the eFS-identified founder cell enhancers, no individual motifs or combinations thereof met our statistical significance criteria of AUC ≥ 0.65 and FDR ≤ 0.1, although a few combinations for known and candidate mesodermal regulators narrowly missed our thresholds ( Supplementary Table 7 ).
FCM enhancers exhibited enrichment for a variety of motifs (among them Twi and Trl) in combination with a Lmd motif, supporting the previously observed enrichment of these motifs in Lmd ChIP-sequencing (ChIP-seq) peaks 35 . We also observed many significantly (AUC ≥ 0.65, FDR ≤ 0.1) enriched motif combinations (many involving the uncharacterized zinc-finger protein CG7928) not found in the Lmd ChIP-seq study 35 . As eFS data are not constrained by occupancy by a particular transcription factor, they allow for more unbiased identification of regulatory motifs. We also observed enrichment of many motif combinations comprising a master regulator and a factor with either ubiquitous or mesoderm-specific expression at the appropriate stage but no known role in mesoderm development (for example, schlank and Lola-PK), suggesting previously unidentified regulators of mesodermal expression ( Fig. 5a and Supplementary Fig. 7) .
classifier to predict mesodermal enhancer activity
We developed a machine learning approach to model whether cCRMs will be active or inactive in the mesoderm or specifically in FCMs. We selected the mesodermal transcription factor binding site motifs, independently in tenfold cross-validation (we split cCRMs into ten equally sized sets, and in each of ten iterations we used 90% of the sets to learn discriminatory motifs and withheld the remaining 10% for subsequent testing as described below), that were most discriminatory in distinguishing active versus inactive cCRMs (Online Methods). We then trained a naive Bayes classifier 43 (Fig. 5b) based on the number and quality of npg matches to the discriminatory motifs, independently for whole mesoderm, FCMs and founder cells.
We assessed the accuracy of our models by tenfold crossvalidation (in each of the ten iterations, the 90% of the cCRMs that we used to learn discriminatory motifs were also used to train the classifier, and the remaining 10% were used to test the accuracy of the classifier). The whole-mesoderm model achieved an AUC of 0.74 (P = 3.9 × 10 −4 , Wilcoxon-Mann-Whitney test) using 12 discriminatory motifs, and the FCM-specific model achieved an AUC of 0.93 (P = 1.2 × 10 −6 , Wilcoxon-Mann-Whitney test) using 3 motifs. These models outperformed ones based solely on previously known cis-regulatory motifs for mesoderm and FCMs (AUC of 0.59 and 0.72, respectively; Supplementary Note 2). We found no statistically significant (P < 0.05) classifier for founder cells.
To demonstrate the practical utility of our models, we tested whether they could predict the activity of cCRMs whose activity had not been measured by eFS. We tested 39 classifier predictions by traditional reporter assays. Six of 10 cCRMs predicted to be active enhancers in mesoderm drove coexpression of GFP with CD2 ( Fig. 5c and Supplementary Fig. 9 ), 19 of 29 cCRMs predicted to be inactive drove no expression in CD2 + cells and 9 of the 10 remaining predicted negative cCRMs drove limited coexpression at stages 11-12 (Supplementary Fig. 9 ). Many of the twi:CD2 + eFS-positive (DESeq P adj < 0.1) enhancers in the training set exhibited 'widespread coexpression' with CD2 and fewer exhibited 'limited coexpression' , and accordingly our classifier performed better in predicting the activity of cCRMs with 'widespread coexpression' .
discussion
Our results demonstrate the utility of eFS for highly parallel testing of cCRMs for tissue-specific enhancer activity. No single data type (sequence-specific transcription factor binding, histone modifications or DHS) was most enriched across all three tissues (Supplementary Fig. 6 ). Moreover, none of the different classes of genomic features that we used to prioritize cCRMs for testing by eFS (cCRMs identified by ChIP, CBP-bound regions and DHS) were significantly enriched (P < 0.1) among active cCRMs considering each of the three mesodermal cell populations or their nonredundant union ( Supplementary Table 8 ). It is perhaps not surprising that these regions were not enriched in either the Mef2-I-E D5 :CD2 + GFP + or duf:CD2 + GFP + data, as FCMs and founder cells are relatively rare cell types and also because many of the putative regulatory regions might drive expression in other cell types as the adjacent genes are often expressed in additional cell types or at other time points.
Future studies will be needed to determine the regulatory functions of the putative mesodermal transcription factors suggested by the motif analysis results for eFS-identified enhancers in whole mesoderm and FCMs. The enrichment of binding sites for PcG and trxG recruitment factors, and combinations thereof with ubiquitously expressed and mesoderm-specific transcription factors, suggests that regulatory competence of enhancers requires binding sites of chromatin factors together with those of tissue-specific transcription factors.
Our classifier analysis results indicate that cis regulation in FCMs is specified by a smaller set of transcription factors than those used in regulation of a broader class of mesodermal genes expressed in a wider range of cell types, each of which might use different cisregulatory codes 6, 44 (Supplementary Fig. 8b,c) . Likewise, the lack of a significant (P < 0.05) classifier for founder cells is likely due to npg heterogeneity of founder cells and their associated enhancers 37, 44 ; eFS using CD2 driver lines specific to subsets or even unique founder cells should aid in the analysis of founder cell-specific cis-regulatory codes. Our results on enrichment of various histone modifications (Supplementary Note 3) are consistent with the model that there exist different classes of active enhancers that are enriched for different sets of histone modifications 26 .
Here we applied the eFS technology to discover muscle enhancers. However, eFS can be used to test cCRMs in any cell type that has at least one known enhancer, by constructing CD2 driver lines using enhancers active in those cell types. eFS can be used to screen cCRMs without any prior experimental evidence (such as ChIP data). Moreover, eFS can be adapted for use in other organisms; the phiC31 integrase system has been used successfully in other species, including zebrafish 45 , human and mouse cells 46 , and mice 47 . In addition, eFS could be implemented using a different site-specific recombinase or other transformation method. Broader application of eFS should greatly expedite and expand the repertoire of well-defined enhancers and facilitate the development of a more comprehensive picture of their landscape and organization of CRMs across genomes.
methods
Methods and any associated references are available in the online version of the paper.
Accession code. Gene Expression Omnibus: GSE41503.
Note: Supplementary information is available in the online version of the paper. nAture methods online methods PCR amplification of cCRMs. The composition of our cCRM library is detailed in Supplementary Note 2. All cCRMs were chosen to be 900-1,100 bp long to avoid potential PCR bias. A two-step PCR amplification was used to include Gateway attB sites, and specific forward and reverse sequencing primers with Phusion enzyme (New England BioLabs) using D. melanogaster OreR genomic DNA as template, followed by amplification with common PCR primers (SEQ1 and SEQ2), as described in Supplementary Note 2.
Design of reporter vector pEFS-Dest. We created the vector for eFS, pEFS-Dest (Supplementary Note 1) , by blunt-end cloning the 1.8 kb HindIII-SpeI fragment of pPelican 48 (containing a nuclear-localized GFP reporter construct with a gypsy insulator element upstream of the multiple cloning site (MCS) and minimal promoter) into pWattB, then replacing the MCS with a cassette providing attR1 and attR2 sites for Gateway cloning. pWattB was made by inserting (i) the phiC31 attB site from Streptomyces lividans 20 and (ii) the mini-white gene into the small cloning vector pSP73 (Promega). The reporter cassette comprises the Hsp70 minimal promoter driving expression of a nuclear localization signal-tagged EGFP gene with an SV40 polyadenylation sequence 48 .
Purification, normalization and cloning of cCRM library into eFS reporter vector. Aliquots of all PCRs were run on agarose gels with High DNA Mass Ladder (Invitrogen) and quantified using Quantity One software (Bio-Rad). Equal masses of each 900-1,100 bp band were pooled, precipitated, gel-purified and then cloned as a pool using Gateway BP Clonase II (Invitrogen) into pDONR221 (Invitrogen). Cloning reactions were transformed into E. coli Top10 cells (Invitrogen) and plated on LB agar with kanamycin. A plasmid pool was purified from the resulting colonies, from which the combined inserts were cloned using Gateway LR Clonase II (Invitrogen) into pEFS-Dest. Transformed cells were plated on LB agar with ampicillin, yielding colonies from which the final library plasmid pool was prepared for embryo injection.
Generation of CD2 vector pETWCD2.
A minimal promoter was fused to rat CD2 and subsequently cloned into P-element transformation vectors by PCR-amplifying the TATA box from pUAST-NTAP and CD2 from twi-CD2 14 . These PCR products served as templates for an assembly PCR, the product of which was subcloned into pCR (Invitrogen), sequence-verified, digested with NheI and cloned into XbaI-digested pETWN 49 , resulting in our CD2 vector pETWCD2. Primer sequences are provided in Supplementary Note 2.
Fly embryo injections and husbandry. The pooled plasmid cCRM library was injected posteriorly into syncytial embryos carrying the nos-φC31\int.NLS transgene 50 on the X chromosome and the attP40 insertion 51 on the second chromosome. Surviving males were crossed to excess y w virgin females. Transformant male progeny were selected by eye color. We collected several thousand transformant males and, separately, several thousand virgin females from each tissue-specific CD2 line of interest. These flies were combined in population cages ~36 h before the beginning of embryo collections. Population cages were collected from twice 'prelays' to minimize the presence of older embryos due to retention of fertilized eggs by females, then two collections of 2 h (for twi:CD2 sorting) or 2.5 h (for Mef2-I-E D5 :CD2 and duf:CD2 sorting) were performed. These plates were aged 10-11 h at 18 °C, after which embryos were collected and dechorionated, and single-cell suspensions were prepared for FACS.
Fluorescence-activated cell sorting. We modified a previous protocol for isolation of single cells for FACS from live Drosophila embryos at stage 11 (ref. 52) by incorporating a step in which dissociated cells are resuspended in Drosophila cell culture medium and incubated on ice with Alexa Fluor 647-conjugated anti-rat CD2 (AbD-Serotec, MCA154A647; 1:200), as described in Supplementary Note 2. After collection of cells by centrifugation, samples were filtered with Nytex mesh and supplemented with DAPI. Cells were washed, and then analyzed and separated by FACS (Supplementary Note 2) . cCRM insert amplifications from collected cells. Crude cell extracts were pooled according to sample where necessary to achieve sufficient numbers for accurate quantification of insert abundance ( Supplementary Fig. 2 and Supplementary Note 2) , then split fivefold before nested PCR amplification to recover library inserts from genomic DNA (Supplementary Fig. 2) . PCRs were performed using KAPA Hi-Fi HotStart ReadyMix (Kapa Biosystems), as described in Supplementary Note 2. PCR products were agarose gel-purified, quantified by NanoDrop and used for Illumina library preparation.
Illumina sequencing. Illumina sequencing libraries were prepared using minor modifications of standard protocols 53 and the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina). Pooled PCR product was sonicated by Covaris S2 as described 53 , and then end-repaired with the End-IT DNA End-Repair Kit (EpiCentre Biotechnologies) and A-tailed with Klenow exo − (New England BioLabs). Standard adaptors (Index PE Adaptor Oligo Mix) were ligated using Quick T4 DNA Ligase (New England BioLabs). Ligation products were size-selected from agarose gels, and quantified and checked for concentration and size distribution by Agilent 2200 TapeStation. Enrichment PCRs were performed using Phusion thermostable polymerase (New England BioLabs), as described in Supplementary Note 2.
Purified enrichment PCR products were assessed by Agilent 2200 TapeStation and submitted to the Partners Center for Personalized Genetic Medicine for concentration measurement by PicoGreen fluorescence and quantitative (q)PCR, followed by equimolar index pooling and sequencing (50-base single-end read) on the Illumina HiSeq 2000.
Mapping Illumina sequencing reads. We used segemehl version 0.0.9.4 (version as of 15 August 2012 was 0.1.3) 23 with parameter settings -M 100 -E 5 -D 2 -A 80 to map Illumina sequencing reads to the D. melanogaster genome. For cCRM detection, we required: (i) ≥1 read from each of the 5′ and 3′ ends; (ii) ≥5 positions covered by center reads (that is, without the SEQ1 or SEQ2 primers); and (iii) ≥10 total reads. Where overlapping cCRM windows contributed indistinguishable reads to the same genomic regions, we used the unambiguous end reads as weights for dividing the reads that map to overlapping cCRM windows. Analysis of random npg sets of genomic windows matched for length, sequence context (for example, intronic and intergenic) and G+C content to our foreground windows indicated that the FDR for cCRM detection was less than 5 × 10 −5 .
Statistical analysis of eFS data.
We collected the number of reads mapped to each cCRM for each replicate population and control 'input' population, and filtered out cCRMs not detected in any input sample replicate. Enrichment and statistical significance were calculated using DESeq 24 with standard parameters and size factor estimation, as described in Supplementary Note 2.
Statistical analysis of genomic features. For a given type of genomic feature, we calculated the scores for each cCRM as the weighted average of the score (for example, ChIP signal intensity) for feature intervals that overlap the peak as reported in the published Browser Extensive Data (BED) or Wiggle Track Format (WIG) file associated with that experiment. We defined the weights by the amount of overlap (in base pairs) between the cCRM and the feature's genomic coordinates. All comparisons of enrichment (or depletion) of various genomic marks were performed by calculating enrichment in the eFS-positive enhancers (DESeq P adj < 0.1) as compared to an equally sized set of inactive cCRMs (DESeq P adj > 0.8) chosen from the bottom of the ranked list (ranked by decreasing fold-enrichment value). The statistical significance of any such enrichment (or depletion) was determined as P < 0.05 by Wilcoxon-Mann-Whitney U test.
DNA sequence motif over-representation analysis. We compiled a dictionary of 567 publicly available Drosophila transcription factor binding site motifs 6, [35] [36] [37] [38] . Motifs were trimmed, redundant motifs were removed and motif exemplars were chosen, as described in Supplementary Note 2. To identify over-represented motifs in the twi:CD2 + GFP + , Mef2-I-E D5 :CD2 + GFP + and duf:CD2 + GFP + foreground (FG) sequence sets, we used PhylCRM and Lever 19 . Lever calculates the over-representation of individual motifs or combinations thereof, according to their density and evolutionary conservation, as quantified by the PhylCRM scoring scheme 19 , in each FG sequence set as compared to a random set of background (BG) sequences. BG sets were chosen to be about 20 times the size of the FG sets, and matched for length, G+C content and repeat content. All settings were as previously described 54 , except that repeats were not masked and length correction was not used because all sequences were roughly the same length. Any motif that did not have occurrences in at least one-quarter of the FG sequences was removed from further consideration. We then used Lever to inspect the FG sets for overrepresentation of all single and pairwise combinations of the resulting 86-exemplar motif dictionary. Motif PWMs are provided in Supplementary Table 7 .
Classifier analysis. For each cCRM, we generated a feature vector of scores that quantify the presence of motif matches for each PWM in the motif exemplar dictionary. The score for a particular PWM and a particular cCRM was defined as the sum of the logodds ratios of PWM matches in the cCRM sequence that exceeded a permissive match threshold (log-odds ratio > 3.0). For classification we used the Gaussian naive Bayes implementation in the scikit-learn package 55 for Python (Supplementary Note 2) . As for the motif over-representation analysis, positive cCRMs are those with DESeq P adj < 0.1; here, negative cCRMs are those from an equally sized set chosen from the bottom of the cCRM list ranked by eFS P adj value. To evaluate classification accuracy, we split the labeled cCRM feature vectors into training and test sets using stratified tenfold cross-validation. Feature selection was performed independently for each of the folds: in each, the k motifs with the highest individual AUC values in the training set were selected. The classifier was then trained using features corresponding only to those k motifs. We evaluated performance across multiple values of k and selected the value that maximized performance accuracy in cross-validation tests.
Traditional reporter assays. Homozygous or balanced heterozygous transformant males were crossed to homozygous twi:CD2 females in small population cages, and broad collections (~2-17 h after egg deposition) of embryos were fixed and stained for immunofluorescence by standard protocols 49 (Supplementary  Note 2) . Stained embryos were imaged with a Zeiss Imager Z1 with Apotome in optical sectioning mode. Coexpression of GFP with CD2 ( Supplementary Table 5 ) was evaluated in individual optical sections with the annotator being blind to the predicted activity of the cCRMs. Coexpression was observed as GFP and CD2 being present in the same cells because GFP in these embryos is nuclear and CD2 is expressed on the cell surface. For validations of CD2 − eFS-positive cCRMs as being active enhancers, we assayed for activity anywhere in the embryo at this developmental stage.
